Original Research
This article examines the relationship between U.S. Food and Drug Administration (FDA) approval and the publication of OS evidence to understand better the risks and benefits of delaying approval until OS evidence is available.
Original Research
Glioblastoma (GB) treatment remains challenging because of recurrence and poorly defined treatment options after first-line therapy. To better understand real-world application of treatment paradigms and their impact on outcomes, the authors describe patterns of GB treatment, outcomes, and use of cancer-related healthcare resource in the USA.
